Randomized phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations: NEJ005/TCOG0902
Shunichi Sugawara(Sendai Kousei Hospital), T. Nukiwa(Tohoku University), Koichi Hagiwara(Jichi Medical University), Akihiko Gemma(Nippon Medical School), Hiroshi Isobe, Kunihiko Kobayashi(Saitama International Medical Center), Koichi Minato, Ichiro Kinoshita(Hokkaido University), Akira Inoue(Tohoku University Hospital), Toshiyuki Harada(Hokkaido hospital), Satoshi Oizumi(Hokkaido University), Ken‐ichi Ito(Niigata City General Hospital), Yasuko Fujita, Masaru Nishitsuji(Ishikawa Prefectural Central Hospital), Satoshi Morita(Kyoto University), Hirohisa Yoshizawa(Niigata University Medical and Dental Hospital), M Kurihara(Hellenic Cooperative Oncology Group), M. Harada, Makoto Maemondo(Miyagi Prefectural Hospital Organization)
Cited by 111
Related Papers
Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
|New England Journal of Medicine|2010|5.6k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial
|The Lancet|2021|1.5k
Tumor-infiltrating DCs suppress nucleic acid–mediated innate immune responses through interactions between the receptor TIM-3 and the alarmin HMGB1
|Nature Immunology|2012|832
Osimertinib with or without Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
|New England Journal of Medicine|2023|695